[A24-112] Apremilast (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V
Last updated 17.02.2025
Project no.:
A24-112
Commission:
Commission awarded on 18.11.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Skin and hair
Children and adolescents from the age of 6 years and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for systemic therapy
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-112
| Project no. | Title | Status |
|---|---|---|
| A20-44 | Apremilast (Behçet’s disease) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A15-09 | Apremilast - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |